Skip to main content
NIH funding notice RFA-MH-21-170

Limited Competition to Convert the CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Study Cohort to a Research Resource (R24 - Clinical Trial Not Allowed)

Closed on May 10, 2021.

Posted
March 8, 2021
Close date
May 10, 2021
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,052,994 in first-year total cost, median $2,052,994.

Most frequent study sections

  1. Special Emphasis Panel[ZMH1 ERB-G (09)]1

Most frequent institutions

  1. UNIVERSITY OF CALIFORNIA, SAN DIEGO1
Competing awards under RFA-MH-21-170 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2022CHARTER Plus: A resource for cutting-edge research on neurological function and mental health in people with HIV and substance use disorders across the lifespan1R24MH129166-01ELLIS, RONALD J.LETENDRE, SCOTT LUNIVERSITY OF CALIFORNIA, SAN DIEGO, CA$2,052,994ZMH1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.